Avantium appoints Gunnar Staaf as CEO Pharma
Strengthening of leadership team to prepare Pharma business for spin-out
According to the company, the appointment is an important step in Avantium’s plan to spin-out its pharmaceutical business. The company intends to create a stand-alone pharmaceutical company based on its offering of proprietary crystallization services and systems to customers in the pharmaceutical and biotechnology sector as well as the development of improved forms of existing drugs. After the spin-out of its pharmaceutical business, Avantium will focus on its cleantech and chemicals activities, including its Furanics bioplastics and biofuels program and offering of high-throughput catalysis services & systems.
Most read news
Topics
Organizations
Other news from the department people
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.